论文部分内容阅读
目的研究糖尿病视网膜病变(DR)患者、孔源性视网膜脱离(RD)患者和眼球破裂伤患者玻璃体中色素上皮衍生因子(PEDF)水平的变化。方法我们采用ELISA(酶联免疫吸附测定)双抗体夹心法测量了35名患者(共36只眼)玻璃体中色素上皮衍生因子(PEDF)的含量。其中,收集了16名(17只眼)欲行玻璃体切割的糖尿病视网膜病变患者、11名孔源性视网膜脱离患者和8名急诊眼球破裂伤患者的玻璃体样本(作为正常对照组)。结果糖尿病视网膜病变(DR)患者玻璃体中PEDF浓度为1.15±0.23μg/ml;孔源性视网膜脱离(RD)组3.41±0.71μg/ml;正常对照组(急诊眼球破裂伤患者的玻璃体样本)1.71±0.39μg/ml。孔源性视网膜脱离(RD)组PEDF水平明显高于糖尿病视网膜病变(DR)组(P<0.001)和眼球破裂伤组(正常对照组)(P<0.05)。糖尿病视网膜病变组增殖期病变(PDR)组PEDF水平为0.88±0.21μg/ml,明显低于非增殖期病变(NPDR)组为2.43±0.37μg/ml(P<0.01)。另外PEDF在活动期(active)糖尿病视网膜病变患者水平(0.70±0.22μg/ml)明显低于非活动期(inactive)糖尿病视网膜病变患者水平(1.79±0.35μg/ml)(P<0.05)。结论PEDF可能是阻止新生血管生成因子之一,并且低水平的PEDF可能导致DR患者新生血管的产生进而进入活动期。此外RD患者较高水平的PEDF显示对于脱离的视网膜,PEDF可能起着一个神经元保护作用。PEDF对于血管增生性眼病具有潜在的治疗价值。
Objective To investigate the changes of vitreous pigment epithelium-derived factor (PEDF) in patients with diabetic retinopathy (DR), rhegmatogenous retinal detachment (RD) and patients with ocular rupture. Methods We measured vitreoretinal pigment epithelium-derived factor (PEDF) levels in 35 patients (36 eyes) using ELISA (enzyme linked immunosorbent assay) double antibody sandwich method. Among them, 16 (17 eyes) patients with vitreoretinal diabetic retinopathy, 11 rhegmatogenous retinal detachment patients and 8 vitreous samples of emergency eyeball rupture patients (as a normal control group) were collected. Results The PEDF concentration in the vitreous was 1.15 ± 0.23μg / ml in diabetic retinopathy (DR) and 3.41 ± 0.71μg / ml in rhegmatogenous retinal detachment (RD) group. The normal control group (vitreous body sample in emergency eyeball rupture) was 1.71 ± 0.39 μg / ml. PEDF levels in rheumatoid retinal detachment (RD) group were significantly higher than those in diabetic retinopathy group (P <0.001) and ocular rupture group (normal control group) (P <0.05). The PEDF level in PDR group was 0.88 ± 0.21μg / ml, which was significantly lower than that in NPDR group (2.43 ± 0.37μg / ml, P <0.01). In addition, the level of PEDF in patients with active diabetic retinopathy (0.70 ± 0.22μg / ml) was significantly lower than that of patients with inactive diabetic retinopathy (1.79 ± 0.35μg / ml) (P <0.05). Conclusions PEDF may be one of the factors that block the neovascularization, and the low level of PEDF may lead to the generation of new blood vessels in DR patients and then enter the active phase. In addition, higher levels of PEDF in patients with RD show that PEDF may play a neuroprotective role in the detachment of the retina. PEDF has potential therapeutic value for angiogenic eye disease.